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Abstract The gp51-p30 glycoprotein constituting BLV envelope
was expressed in Sf-21 insect cells by means of recombinant
baculoviruses. Post-infection cell lysates were analyzed, in order
to define the immunologic reactivity of recombinant products.
Oligosaccharide chains, containing N-acetylglucosamine, man-
nose, galactose and sialic acid were found on recombinant gp51-
p30. In order to investigate the timing of transcription and
translation of the glycoprotein, kinetic assays were carried out on
cell lysates and directly in situ on Sf-21 cells during the course of
baculovirus infection. The use of different solubilizing reagents
was also evaluated in order to rescue recombinant glycoprotein
from its subcellular location.
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1. Introduction
Baculovirus expression vector system (BEVS) is generally
regarded as one of the most promising and versatile expres-
sion systems currently available [1]. Insect cell lines usually
allow production of recombinant proteins with very large
yields, usually not reached with other expression systems. A
peculiar feature of this expression system is its ability to carry
out post-translational modi¢cations on recombinant proteins
[2,3]. Particularly relevant to the study presented here is the
research on the expression of fowl plaque virus hemagglutinin
[2].
Bovine leukemia virus (BLV) is a retrovirus, belonging to
BLV-HTLV genus, responsible for enzootic bovine leukosis
(EBL), one of the most di¡used retroviral infections of do-
mestic cattle. The disease is characterized by evolution of
persistent lymphocytosis, and in some cases B-cell lymphomas
may develop [4,5]. BLV envelope proteins can elicit a strong
and long-lasting immune response in infected cattle [4]. In-
deed, earliest phases of BLV infection can be diagnosed by
serological techniques, based on gp51 antibody detection [6],
as well as by molecular techniques, using DNA probe hybrid-
ization [7] and in vitro ampli¢cation of viral genome sequen-
ces [8,9]. Moreover, gp51 was also used to produce vaccines
against BLV infection. Howewer, a fully protective vaccine
against BLV has not been obtained yet [10,11].
One of the main topics currently under investigation in
biotechnology is the search for eukaryotic expression systems
able to synthesize glycoproteins carrying oligosaccharide
chains very similar to those found on native glycoproteins.
Glycosylation is known to play a main role in conferring bio-
logical properties to env proteins of BLV [12,13], so this pro-
tein can be considered a suitable model to be used in this
study. The aim of this paper is the analysis of recombinant
env protein of BLV, expressed by engineered BEVS. We chose
this model to evaluate expression of glycosylated proteins in
insect cells and to compare recombinant gp51-p30 to the na-
tive BLVenv glycoprotein synthesized by mammalian cells.
2. Materials and methods
2.1. Bacterial strains and plasmids
pGEM-1224 plasmid, containing a BglII-BglII fragment (nucleo-
tides 5084^6308) of BLVenv gene, was kindly provided by S. Gaudi
(Fondation Merieux, Lyon, France). TA-cloning of the PCR product
was carried out in pCRII plasmid (Invitrogen). Both pCRII and
pGEM-1224 plasmids were ampli¢ed in JM 109 bacterial strain, while
the baculovirus shuttle plasmid used in this work, pBlueBacHis (In-
vitrogen), was ampli¢ed in Top 10 bacterial strain (Invitrogen), ac-
cording to current protocols [14,15].
2.2. Insect cell lines and viral vector
Sf-9 or Sf-21AE cells [16] were grown in Grace’s medium (Invitro-
gen) or in SF900 medium (Gibco), supplemented with 5% fetal calf
serum (FCS) and gentamycin (50 mg/ml). In some experiments, a
Trichoplusia ni cell line, High 5, [17] was also used. Wild-type
AcMNPV (Autographa californica multiple nuclear polyhedrosis virus)
stocks (Invitrogen), as well as recombinant baculoviruses produced in
this experiment, were propagated in Sf-9 or Sf-21 cells as described by
Summers and Smith [18].
2.3. Cloning in pBlueBacHis vector
BLVenv insert (nucleotides 5131^6158) was ampli¢ed by polymerase
chain reaction (PCR) from pGEM-1224 plasmid [7] by means of two
synthetic oligonucleotides: SP6 (Promega) and a speci¢c BLVenv
(6158-CCGATTATCCTTATCCGAATCTTGTTC-6131) primer.
Ampli¢ed DNA, cut by NcoI-HindIII restriction endonucleases
(1100 bp), was cloned in pBlueBacHis-B shuttle vector, downstream
the polh promoter cassette. DNA ligation, transformation and selec-
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tion of recombinant Top 10 bacteria were carried out according to
current protocols [15]. Before cotransfection, recombinant plasmids
were extracted, analyzed and sequenced, in order to verify proper
insert positioning in shuttle plasmid [19].
2.4. Production, screening and puri¢cation of recombinant
baculovirus strains
Linearized AcMNPV DNA and pBlueBacHis-env plasmid were co-
transfected into Sf-21 cells by cationic liposomes [20]. Recovered
supernatants underwent plaque screening by a colorimetric method
based on lacZ gene expression, looking for polh3 (occ3) and blue
plaques [21]. Supernatants were also assayed for recombinant DNA
by PCR, using a pair of commercial ‘F’ and ‘R’ primers (Invitrogen)
or a speci¢c ‘SecBac’ (CTAGCATGACTGGTGGACAG) and ‘R’
primers pair. Plaque assays and PCR ampli¢cation were carried out
twice on putative positive supernatants.
2.5. Small scale infections
Sf-21 or Sf-9 cells were plated and infected at low multiplicity of
infection (MOI) with aliquots of recombinant viral supernatants (A1,
A2, 23), and rescued at 72 h post infection (p.i.) or at 90% cell lysis. In
kinetic experiments, infections were stopped 6^96 h p.i., and samples
were processed as described below.
2.6. SDS-PAGE, Western and lectin blot analysis
Cell lysates were resolved on 14.9% acrylamide gels according to
Neville’s protocol [22]. Cell pellets and lyophilized infection superna-
tants were directly solubilized in sample bu¡er (¢nal concentrations:
10 mM Tris-HCl, pH 8, sodium dodecylsulfate 2%, L-mercaptoetha-
nol 2%). Uninfected Sf-21 cells as well as Sf-21 cells infected with
wild-type AcMNPV were similarly processed and run as negative
controls. Puri¢ed gp51, obtained from persistently infected fetal
lamb kidney cells (FLKgp51), was kindly provided by M. Merza
(Dept. of Veterinary Virology, Uppsala, Sweden), and used as positive
control in some experiments. Equal amounts of each sample were run
on SDS-PAGE gels and analyzed by Coomassie blue or silver stain-
ing. Similar SDS-PAGE gels were blotted on nitrocellulose sheets as
described [23], and probed overnight with MAb 51/05 (1:1000^
1:4000) [24] or with pools of BLV-positive or negative bovine sera,
previously collected from dairy cattle in some Northern Italy farms.
Reactions were revealed by secondary peroxidase-conjugated antibod-
ies (1:500^1:1000), and colorimetric reactions were developed with
H2O2 and K-chloro-naphthol (Bio-Rad). A complete series of protein
lysates, similarly blotted on nitrocellulose ¢lters, was assayed with a
panel of 17 biotinylated lectins (Vector) [25], in order to assess the
type of glycosylation on recombinant molecules. Lectins and their
speci¢cities are presented in Table 1.
2.7. In situ analysis: primed in situ labelling (PRINS) on speci¢c
mRNAs and indirect immuno£uorescence analysis
8^10U105 Sf-9 cells were allowed to adhere on sterile glass slides
pretreated overnight with 20% FCS in SF900 medium and infected at
a low MOI with recombinant baculovirus strain 23. Slides were ¢xed
at di¡erent times p.i. (0, 6, 12^96 h p.i.) with 4% paraformaldehyde in
PBS, in order to permeabilize the cell membranes. Slides were washed
three times with PBS plus 0.5% Triton X-100, air dried and frozen at
320‡C in sealed polyethylene bags. All reagents were treated with
0.1% diethylpyrocarbonate (DEPC) and current cautions to prevent
mRNA degradation were also taken [15]. Uninfected cell samples
were similarly processed. Samples, predigested with RNase-free
DNase, underwent PRINS reaction by applying primer-mediated re-
verse transcriptase mRNA labelling [26]. Biotinylated cDNAs were
revealed in situ by a colorimetric reaction developed according to
manufacturer’s instructions (Gene-Tect, Clontech). Images were ac-
quired and analyzed by means of both light and confocal microscopy.
A similar complete series of permeabilized cell samples, collected from
recombinant and wild-type infections, was assayed with MAb 51/05 to
evaluate recombinant protein localization. Samples were treated with
blocking solution (BSA 3% and 10% normal rabbit serum in PBS)
before incubation with MAb 51/05 (1:100^1:500 in PBS) in a mois-
tened chamber. Reactions were developed with a rabbit FITC-conju-
gated secondary antibody and analyzed by both £uorescent and con-
focal microscopy.
2.8. Antigen solubilization assays
On the basis of kinetic assay results, Sf-21 cells infected with re-
combinant viral strain 23 were recovered at 72 h p.i. and lysed by
di¡erent reagents: 3 M urea; 3 M urea plus 4% Tween-20; 8 M urea;
8 M urea plus 4% Tween-20; 4% Tween-20 in PBS; 10% Tween-20 in
PBS; 2% octyl-L-D-glucopyranoside in PBS. After treatment, cell ly-
sates, clari¢ed by low speed centrifugation, were extensively dialyzed
against distilled H2O, lyophilized and resuspended in distilled sterile
H2O. Protein concentration was determined by BCA assay (Pierce),
and equal amounts of proteins were run on 14.9% SDS-PAGE gels, as
described. After silver staining, recombinant protein was quanti¢ed by
densitometry (Cream 4.0; Chem-en-tec).
3. Results and discussion
3.1. Recombinant gp51-p30 expression
The BLVenv gene codes an env precursor protein, gp72. The
N-terminus is processed to form gp51, external glycoprotein,
while the C-terminus corresponds to the transmembrane pro-
tein p30 [5]. The cloning strategy is shown in Fig. 1. The
insert, corresponding to nucleotide position 5431^6158, was
cloned in pBacBluHis (polylinker version ‘B’), maintaining
the primitive env reading frame. Nucleotide sequence of re-
combinant plasmids was determined before cotransfection.
A 1:3 mix of linearized AcMNPV [20] and pBlueBacHis-
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Table 1
Lectin blot assays
Lectin Abbreviation Binding speci¢city A1 A2 23 FLK-gp51
Concanavalin A ConA K-Man + + + +
Pisum sativum agglutinin PSA K-Man + + + +
Lens culinaris agglutinin LCA K-Man + + + +
Peanut agglutinin PNA GalL1-3GalNAc (O-linked) 3 3 3 3
Ricinus communis agglutinin RCA L-Gal, L-GalNAc 3 3 3 +
Sophora japonica agglutinin SJA Terminal L-Gal, L-GalNAc 3 3 3 3
Soybean agglutinin SBA Terminal L-Gal, L-GalNAc 3 3 3 3
Dolichos bi£orum agglutinin DBA K-GalNAc 3 3 3 3
Bandeiraea simplicifolia agglutinin BSA K-Gal, K-GalNAc 3 3 3 +
Wheat germ agglutinin WGA Terminal NeuNAc (GlcNAcL1-4) + + + +
Triticum vulgaris agglutinin SuccWGA t-[(L-1,4)GlcNAc]2 3 3 3 +
Ulex europeas agglutinin UEA K-Fuc 3 3 3 3
Phaseolus vulgaris agglutinin PHA-E GalL1-4GalNAc + + + +
Phaseolus vulgaris agglutinin PHA-L Tri-tetra-antennary complex N-linked
oligosaccharides
3 3 3 +
Datura stramonium agglutinin DSA GalL1-4GalNAc + + + +
Maachia amurensis agglutinin MAA K-2,3 Sialic acid + + + +
Galanthus nivalis agglutinin GNA Terminal K-Man 3 3 3 3
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BLVenv DNA was mixed with cationic liposomes [21]. Lip-
osome-mediated Sf-21 cell infection was allowed to proceed
for 48 h. Putative recombinant baculoviruses were screened by
plaque assay on agarose-X-gal medium [21].
PCR analysis with two semi-nested primer pairs (F+R,
1100 bp; SecBac+R, 838 bp) con¢rmed that the BLVenv in-
sert had successfully replaced polh sequence in three independ-
ent viral plaques, indicated as A1, A2 and 23 (clone 23 is
shown in Fig. 2A).
SDS-PAGE analysis of three recombinant cell lysates
showed a 51^55-kDa band that was absent in wild-type ba-
culovirus-infected cells as well as in the same uninfected insect
cell line (Fig. 2B). Control samples from wild-type infected
cells showed only a 30-kDa band, corresponding to polh
gene product. While gp72, glycosylated precursor of BLV en-
velope protein, is proteolytically processed into gp51 and p30
in mammalian cells, recombinant protein is not cleaved in
insect cells. Bands at low molecular weight, detected by West-
ern blot, might be produced by unspeci¢c intracellular pro-
teolysis.
3.2. Recombinant gp51-p30 analysis
Western blot analysis of A1, A2, 23 cell lysates showed that
the 51^55-kDa band speci¢cally reacted with MAb 51/05, a
monoclonal antibody able to recognize a sequential epitope
mapped at the C-terminus of gp51 BLV antigen. Eight major
epitopes have been mapped on gp51 (Fig. 1): conformational
epitopes C, F, G, H, are located at the gp51 N-terminus, while
A, B, D, E sequential epitopes are found at the C-terminus
[27]. Humoral immune responses raised by BLV infection are
directed against gp51 conformational epitopes [28] : in fact,
A1, A2, 23 and FLK-gp51 failed to react with a pool of
bovine BLV-positive sera in Western blot assay (Fig. 3).
3.3. Recombinant gp51-p30 glycosylation pattern analysis
Glycosylation of gp51 antigen has been shown to play a
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Fig. 3. Western blot and lectin blot analysis of recombinant glyco-
protein gp51-p30. Top: Western blot analysis of cell lysates with the
Mab 51/05 and a BLV-positive bovine serum. From the left, in
both panels: Sf-21 cells infected by recombinant strains 23, A1, A2;
uninfected Sf-21 cells and native gp51 from FLK cells. Bottom:
Lectin blot analysis of recombinant gp51-p30 glycoprotein with bio-
tinylated lectins WGA (wheat germ agglutinin) and PHA-E (eryth-
rocyte-phyto-hemo-agglutinin). From the left, in both panels: native
gp51 from FLK cells, uninfected Sf-21 and Sf-21 cells infected by
recombinant strains A1, A2 and 23.
Fig. 2. Con¢rmation of a positive recombinant plaque (recombinant
viral strain 23). A: PCR ampli¢cation of recombinant plaques, us-
ing the primer pair SecBac-R. M: Molecular weight standards
(2600^60 bp); lane 1: mock reaction without viral DNA; lanes 2^6,
8: negative reactions; lane 7: positive ampli¢cation (838 bp). B:
SDS-PAGE analysis of Sf-21 cell lysates. M: Molecular weight
standards (97^14 kDa); Sf-9 uninfected cell lysate; Sf-9 cells in-
fected by wild-type AcMNPV (s: supernatant; p: pellet); Sf-9 cells
infected by recombinant baculovirus (strain 23); polh : polyhedrin
(31 kDa); gp51-p30: recombinant product (51^55 kDa).
Fig. 1. Molecular organization and cloning strategy of BLV env gly-
coproteins. From the top: Hydrophilicity-hydrophobicity plot, also
displaying major epitopes and N-glycosylation sites mapped on env
glycoproteins; BLVenv gene map, showing leader peptide and gp51-
p30 boundary; env region cloned in AcMNPV vector.
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critical role in maintaining native conformation of this BLV
antigen, as shown by immunological studies [29] and, more
strikingly, by failure in protective immunity due to deglycosyl-
ated antigens assayed as subunit vaccines [12,13]. All native
gp51 antigens produced in di¡erent BLV-infected mammalian
cells were shown to be N-glycosylated, while O-glycosylation
was never described on this molecule [25]. Recombinant gp51-
p30 produced in Spodoptera frugiperda cells underwent glyco-
sylation, as shown by lectin blot experiments (Fig. 3). As
shown in Table 1, N-acetylglucosamine, mannose, galactose
and sialic acid residues were found on recombinant protein.
These sugars have also been found on native gp51 puri¢ed
from FLK cells, as well as on gp51 expressed in eukaryotic
cell lines [25]. Fucose and O-linked oligosaccharides were not
found on gp51 from FLK cells, as well as on recombinant
gp51-p30. This latter result may indicate that sugar residues
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Fig. 4. In situ analysis of env mRNA by PRINS and intracellular staining of recombinant gp51-p30 glycoprotein by indirect immuno£uores-
cence. Top, from the left: PRINS labelling of negative cells ; PRINS labelling of mRNAs in infected cells (strain 23, 12 and 24 h p.i.). Second
row: Intracellular detection of gp51-p30 recombinant glycoprotein by £uorescence microscopy, at 24^72 h p.i. Third row: Confocal image anal-
ysis. From the left: Cell morphology; immunostaining of the same ¢eld; superimposed images.
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on recombinant glycoproteins are more likely arranged in N-
linked mono- or bi-antennary chains, and, as shown by PHA-
L lectin lacks reactivity.
3.4. Kinetic analysis of expression
Kinetic analysis of cell lysates showed that recombinant
proteins were poorly detectable at all infection stages, even
though they accumulated mostly in ‘late’ infection phases
(48^72 h p.i.) (data not shown).
Scarce reactivity of recombinant gp51-p30 is not imputable
to ine¡ective transcription and translation, as shown by both
PRINS and immuno£uorescence results (Fig. 4). gp51-p30
mRNA could be already detected at 12 h p.i. and, more
clearly, at 24 h p.i. The recombinant protein became fully
detectable by immuno£uorescence at 48 h p.i. These results
are consistent with current data on polh gene regulation and
expression, suggesting that the formation of intracellular ‘in-
clusion bodies’ may entrap the recombinant antigen in an
insoluble form.
3.5. Solubilization of inclusion bodies
Inclusion bodies are more likely formed when expression
levels of heterologous proteins are very high [30], or in re-
sponse to toxic e¡ects exerted by the expressed product on
host cell metabolism. These considerations are particularly
valid for baculovirus-infected cells, because the polh can drive
the expression of heterologous genes to considerably high lev-
els (up to one third of total cell proteins). Moreover, the
presence of hydrophobic stretches of amino acids in heterol-
ogous proteins, or their improper folding might cooperate in
promoting the intracellular precipitation of recombinant anti-
gens: particularly in late phases of baculovirus infection, when
host cell functions decline [31,32].
In order to improve the detection of recombinant gp51-p30,
crude cell lysates underwent di¡erent solubilization protocols:
urea at di¡erent concentrations (3 M and 8 M), detergents
(4% and 10% Tween-20; 2% octyl-L-D-glucopyranoside) and
combination of urea and detergents (3 M urea plus 4%
Tween-20; 8 M urea plus 4% Tween-20) (Fig. 5).
Best results in glycoprotein solubilization, as determined by
densitometric determination after SDS-PAGE and silver
staining, were achieved by 3 M urea lysis bu¡er (10.1%), fol-
lowed by 4% Tween-20 (5.59%), 10% Tween-20 (5.17%) and
2% octyl-L-D-glucopyranoside (5.41%).
4. Conclusions and perspectives
Recombinant gp51-p30 appears to be glycosylated: the sug-
ar residues on this product are very similar to those identi¢ed
on native glycoproteins [25]. O-linked glycans were neither
found on native gp51 produced in mammalian cells nor on
recombinant gp51-p30. Carbohydrates are more likely ar-
ranged in N-linked oligosaccharides, albeit displaying more
simple structures than glycans found on native glycoprotein.
Howewer, due to the essential role played by glycosylation in
maintaining the conformation of major epitopes present on
native gp51, even small di¡erences in glycosylation patterns
might in£uence reactivity and biologic activity of recombinant
protein [33]. This will require a more detailed analysis on
recombinant gp51-p30.
In the present experiment, both the high e⁄ciency of polh
promoter and the presence of C-terminal hydrophobic amino
acids stretches might have cooperated to determine the gp51-
p30 precipitation in cytoplasmic aggregates. Urea and deter-
gents proved to be useful to solubilize recombinant glycopro-
tein, the former displaying the highest e¡ectiveness. In spite of
several drawbacks, insect cells should be considered a feasible
eukaryote host to express glycoproteins. Our results show
gp51-p30 sugar residues are very similar to those found on
native gp51 expressed in mammalian cells, while nearly all
recombinant and even native glycoproteins ‘made in insect
cells’ were shown to carry N-acetylglucosamine and mannose
residues only [2,3]. To date, human plasminogen appears to be
the unique other recombinant glycoprotein expressed by
BEVS carrying complex-type N-glycans [34]. Present result
might be due to gp51-p30 precipitation in insoluble aggre-
gates, which helps recombinant protein to escape lytic en-
zymes abundantly produced by insect cells [3]. Such a result
will require further investigation, not only to analyze ¢ne
glycosylation patterns on recombinant gp51-p30 but also to
throw new light on insect cells potential in glycan synthesis
and oligosaccharide trimming.
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